Evaluation of the Effects of DracoBelle Nu in Skin Health After Oral Intake
NCT ID: NCT06059534
Last Updated: 2024-01-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
100 participants
INTERVENTIONAL
2023-10-19
2023-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pilot Investigation of a Multinutrient Supplement on Skin Aging and Aging Metabolites in Healthy Women
NCT00541931
A Study to Evaluate the Effect of Lycomato on Skin Attributes in Healthy Participants.
NCT05328388
Clinical Effects of Two Oral Bioactive Collagen Peptides On Skin Properties and Aging Hallmarks
NCT07302789
Clinical Study to Evaluate the Anti-aging Efficacy of Dermial®
NCT05813054
The Effect of Oral Hyaluronic Acid on the Skin
NCT05803083
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The products will be provided in capsules containing placebo or 200 mg of DracoBelleTM Nu. 50 volunteers will ingest the placebo and 50 volunteers will ingest the product DracoBelleTM Nu by oral intake once a day (one capsule a day, preferably in the morning) for 12 weeks. Different parameters will be measured before treatment (D0) and at week 4, week 8, and week 12 after the first oral intake. The parameters that will be measured are related to the skin health and skin aging and will be determined as follows:
* The skin elasticity, firmness and fatigue will be measured by the Cutometer in the face skin area.
* Wrinkles (area, length, depth and volume) and roughness of the skin will be measured by the technology Bio3D-MS in the crows-feet and cheek areas.
* The skin density will be measured to determine the thickness of the epidermis and dermis by echography analysis with the UltraScan Echograph in the face skin area.
* Skin hydration will be measured with the Corneometer in the face skin area.
* The skin barrier effect will be measured by quantifying the transepidermal water loss with the Tewameter in the cheek.
* The alterations of the skin pigmentation (area and number of dark spots, and contrast of the dark spots compared to the skin) will be measured with the technology Bio3D-MS.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
This group will be provided with placebo capsules for comparative purposes.
Dietary supplementation with placebo.
Volunteers will be provided with the placebo capsules. For each volunteer, different age-associated skin parameters will be measured with specialized equipment before the treatment and 4, 8 and 12 weeks after the first oral intake of the product.
DracoBelleTM Nu
This group will be provided with DracoBelleTM Nu capsules, which will be compared to the placebo group.
Dietary supplementation with DracoBelleTM Nu.
Volunteers will be provided with the DracoBelleTM Nu capsules. For each volunteer, different age-associated skin parameters will be measured with specialized equipment before the treatment and 4, 8 and 12 weeks after the first oral intake of the product.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dietary supplementation with placebo.
Volunteers will be provided with the placebo capsules. For each volunteer, different age-associated skin parameters will be measured with specialized equipment before the treatment and 4, 8 and 12 weeks after the first oral intake of the product.
Dietary supplementation with DracoBelleTM Nu.
Volunteers will be provided with the DracoBelleTM Nu capsules. For each volunteer, different age-associated skin parameters will be measured with specialized equipment before the treatment and 4, 8 and 12 weeks after the first oral intake of the product.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Between 35-60 years old (both included).
* With noticeable wrinkles.
* Subjects with absence of any infectious disease within the 4 weeks previous to the study.
* Informed of the purpose and the protocol of the study and signed a written informed-consent form.
Exclusion Criteria
* Consume more than the recommended alcohol guidelines i.e. \>21 alcohol units/week for males and \>14 units/week for females (europa.eu).
* Current smoking habit or history of smoking within the past 1 year.
* History of depression, schizophrenia, alcoholism, drug addiction, or mental illness.
* Current or previous intake of contraceptives, female hormones, obesity drugs, absorption inhibitors, antidepressants, or appetite suppressants.
* History of asthma or autoimmune disease Use of oral hormone therapies ie. cortisone or steroids in the 6 months prior to initiation of the study.
* Abnormal liver function or abnormal renal function.
* Blood pressure \>140/90 mmHg or hypertension with intake of a diuretic.
* Any condition judged by the investigator to be unsuitable for participation in the study.
* Subjects refrain from the intake of other oral supplements, including antioxidants, dietary supplements, etc.
* Subjects do not alter their mode of contraception 6 weeks prior and during the study.
* Subjects refrain from any intense or invasive cosmetic treatment, alone or by a beautician, such as intense masks, peelings, and other treatments.
* Subjects are free to follow their usual routine of day and night care products.
35 Years
60 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bionos Biotech S.L.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Pajuelo Gamez, PhD
Role: PRINCIPAL_INVESTIGATOR
Hospital La Fe
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bionos Biotech S.L.
Valencia, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DracoBelle_2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.